Trial reportBritish journal of cancer2013
KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.
Trial report in British journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 6 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Circulating tumour DNA and its clinical utility in predicting treatment response or survival in patients with metastatic colorectal cancer: a systematic review and meta-analysis.British journal of cancer · 2022Pooled it
- Reliability of BRAF mutation detection using plasma sample: A systematic review and meta-analysisMedicine · 2021Pooled it
- The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.Cancer medicine · 2019Pooled it
- Circulating Cell-Free DNA and Colorectal Cancer: A Systematic Review.International journal of molecular sciences · 2018Pooled it
- Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review.PloS one · 2017Pooled it
- The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis.PloS one · 2017Pooled it
- Prognostic significance of circulating tumor DNA in non-metastatic colorectal cancer.Discover oncology · 2025Article
- Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives.Cancers · 2021Review
- Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.The journal of pathology. Clinical research · 2021Article
- The Application of Circulating Tumor DNA in the Screening, Surveillance, and Treatment Monitoring of Colorectal Cancer.Annals of surgical oncology · 2021Review
- Review
- Article
- Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer.Frontiers in oncology · 2020Review
- Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer.Scientific reports · 2019Article
- Clinical utility of circulating tumor DNA for colorectal cancer.Cancer science · 2019Review
- Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.Cancer medicine · 2019Article
- Liquid Biopsy in Gastrointestinal Cancers.Diagnostics (Basel, Switzerland) · 2018Review
- The Use of Circulating Tumor DNA for Prognosis of Gastrointestinal Cancers.Frontiers in oncology · 2018Review
- Genomic Landscape of Appendiceal Neoplasms.JCO precision oncology · 2018Article
- The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.Oncotarget · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe investigated the clinical implications of KRAS and BRAF mutations detected in both archival tumor tissue and plasma cell-free DNA in metastatic colorectal cancer patients treated with irinotecan monotherapy.
methodsTwo hundred and eleven patients receiving second-line irinotecan (350 mg m(-2) q3w) were included in two independent cohorts. Plasma was obtained from pretreatment EDTA blood-samples. Mutations were detected in archival tumour and plasma with qPCR methods.
resultsMutation status in tumor did not correlate to efficacy in either cohort, whereas none of the patients with mutations detectable in plasma responded to therapy. Response rate and disease control rate in plasma KRAS wt patients were 19 and 66% compared with 0 and 37%, in patients with pKRAS mutations, (P=0.04 and 0.01). Tumor KRAS status was not associated with PFS but with OS in the validation cohort. Plasma BRAF and KRAS demonstrated a strong influence on both PFS and OS. The median OS was 13.0 mo in pKRAS wt patients and 7.8 in pKRAS-mutated, (HR=2.26, P<0.0001). PFS was 4.6 and 2.7 mo, respectively (HR=1,69, P=0.01). Multivariate analysis confirmed the independent prognostic value of pKRAS status but not KRAS tumor status.
conclusionTumor KRAS has minor clinical impact, whereas plasma KRAS status seems to hold important predictive and prognostic information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.